ThromboGenics NV and Novartis AG have announced the launch of Jetrea ocriplasmin in Denmark and Sweden for the treatment of vitreomacular traction including when associated with a macular hole of 400um or less in diameter. ThromboGencis stated in their press release that the wholesale acquisition cost of the drug will be €3,100 for a singl-use vial of 0.125mg, the recommended dose for treatment.